STOCK TITAN

Evolus to Participate in November Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) will present at the Stifel 2023 Healthcare Conference on November 15, 2023, and at the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023. Audio webcasts of the events will be available on Evolus' website, with replays available for 90 days.
Positive
  • None.
Negative
  • None.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November.

 

Event:

 

Stifel 2023 Healthcare Conference

 

Date:

 

Wednesday, November 15, 2023

 

Time:

 

11:30 AM ET

       
 

Event:

 

6th Annual Evercore ISI HealthCONx Conference

 

Date:

 

Tuesday, November 28, 2023

 

Time:

 

9:35 AM ET

Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse is a trademark of Evolus, Inc.
Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor Contacts:

Ned Mitchell

Arbor Advisory Group

Email: ir@evolus.com

Media Contact:

Email: media@evolus.com

Source: Evolus

Evolus will present at the Stifel 2023 Healthcare Conference on November 15, 2023.

Evolus will present at the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023.

The audio webcasts of the events will be available on Evolus' website at www.evolus.com.

The replays of the webcasts will be available for 90 days after the date of each presentation.
Evolus Inc

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.